These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11685727)

  • 1. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report.
    Oh WK; George DJ; Kaufman DS; Moss K; Smith MR; Richie JP; Kantoff PW
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):40-4. PubMed ID: 11685727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
    Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.
    Febbo PG; Richie JP; George DJ; Loda M; Manola J; Shankar S; Barnes AS; Tempany C; Catalona W; Kantoff PW; Oh WK
    Clin Cancer Res; 2005 Jul; 11(14):5233-40. PubMed ID: 16033841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
    Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D
    Urology; 2003 Apr; 61(4):774-80. PubMed ID: 12670564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
    Hussain A; Dawson N; Amin P; Naslund M; Engstrom C; Chen T
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):22-31. PubMed ID: 11685725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary observations of single-agent docetaxel as neoadjuvant therapy for locally advanced prostate cancer.
    Dreicer R; Klein EA
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):45-8. PubMed ID: 11685728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
    Ross RW; Galsky MD; Febbo P; Barry M; Richie JP; Xie W; Fennessy FM; Bhatt RS; Hayes J; Choueiri TK; Tempany CM; Kantoff PW; Taplin ME; Oh WK
    Cancer; 2012 Oct; 118(19):4777-84. PubMed ID: 22282219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
    Kim WY; Whang YE; Pruthi RS; Baggstrom MQ; Rathmell WK; Rosenman JG; Wallen EM; Goyal LK; Grigson G; Watkins C; Godley PA
    Urol Oncol; 2011; 29(6):608-13. PubMed ID: 20022268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
    Clark PE; Peereboom DM; Dreicer R; Levin HS; Clark SB; Klein EA
    Urology; 2001 Feb; 57(2):281-5. PubMed ID: 11182337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
    Vuky J; Porter C; Isacson C; Vaughan M; Kozlowski P; Picozzi V; Corman J
    Cancer; 2009 Feb; 115(4):784-91. PubMed ID: 19130458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate.
    Berry W; Dakhil S; Gregurich MA; Asmar L
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):8-15. PubMed ID: 11685723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
    Shepard DR; Dreicer R; Garcia J; Elson P; Magi-Galluzzi C; Raghavan D; Stephenson AJ; Klein EA
    J Urol; 2009 Apr; 181(4):1672-7; discussion 1677. PubMed ID: 19230915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
    Garzotto M; Higano CS; O'Brien C; Rademacher BL; Janeba N; Fazli L; Lange PH; Lieberman S; Beer TM
    Cancer; 2010 Apr; 116(7):1699-708. PubMed ID: 20143429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer.
    Vuky J; Corman JM; Porter C; Olgac S; Auerbach E; Dahl K
    Oncologist; 2013 Jun; 18(6):687-8. PubMed ID: 23740935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.
    Taplin ME; Bubley GJ; Rajeshkumar B; Shuster T; Ko YJ; Morganstern DE
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):32-9. PubMed ID: 11685726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
    Picus J; Schultz M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
    Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
    BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer.
    Mathew P; Pisters LL; Wood CG; Papadopoulos JN; Williams DL; Thall PF; Wen S; Horne E; Oborn CJ; Langley R; Fidler IJ; Pettaway CA
    J Urol; 2009 Jan; 181(1):81-7; discussion 87. PubMed ID: 19012911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.
    Hussain A; Dawson N; Amin P; Engstrom C; Dorsey B; Siegel E; Guo C
    J Clin Oncol; 2005 Apr; 23(12):2789-96. PubMed ID: 15837994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel in the integrated management of prostate cancer. Current applications and future promise.
    Logothetis CJ
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):63-72. PubMed ID: 12108899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.